Kristian Reich, MD, PhD, discusses the results of two phase 3 clinical trials, BE-READY and BE-VIVID, that tested the efficacy and safety of bimekizumab, a novel IL-17A/IL-17F inhibitor.
Bruce M. Katz, MD, discusses the results of two phase 3 clinical trials on daxibotulinumtoxinA for injection, the development of a onabotulinumtoxinA biosimilar, and the current state and future of cosmetic dermatology practice.
A recent poster abstract investigated the impact of insurance type, such as private or Medicaid, on delay in diagnosis among patients with hidradenitis suppurativa.
In a small study, researchers assessed the safety and efficacy of ustekinumab intravenous induction among patients with severe hidradenitis suppurativa.
Findings from a recent poster abstract presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for abrocitinib, an oral Janus kinase inhibitor.